DDInter1917 DDInter1658
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Vandetanib {u} (Compound) resembles {v} (Compound) Erlotinib
Vandetanib {u} (Compound) treats {v} (Disease) thyroid cancer
Vandetanib {u} (Compound) binds {v} (Gene) FMO1
Vandetanib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Vandetanib {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Vandetanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Vandetanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Vandetanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Vandetanib {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Vandetanib (Compound) resembles Erlotinib (Compound)
Vandetanib (Compound) treats thyroid cancer (Disease)
Vandetanib (Compound) binds FMO1 (Gene)
Vandetanib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Vandetanib (Compound) causes Blood creatinine increased (Side Effect)
Vandetanib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Vandetanib may cause a minor interaction that can limit clinical effects when taken with Esomeprazole
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Vandetanib may lead to a major life threatening interaction when taken with Lefamulin